SBTX

Skinbiotherapeutics PLC

Health Care First-pass screen £25m

330/1000 Overall fit

AI beneficiary 35% 15

Operating leverage 25% 52

Valuation 25% 30

Downside protection 15% 48

First-pass take

Micro-cap UK biotech (life sciences / skin microbiome) with zero AI exposure. Revenue grew 284% to £4.6m driven by acquisitions (Dermatonics, Bio-Tech Solutions) and early-stage partnerships (Croda, Superdrug), with operating loss improving 61% and gross margins expanding to 62%. Net cash position of £4.8m provides downside protection but liquidity risk is high on AIM. No valuation data in document. Does not fit AI investment thesis.

Flags

no-ai-exposurebiotech-early-stageloss-makingnet-cashmicro-cap-aimno-valuation-datapre-commercializationcustomer-concentrationconsolidator-strategygoing-concern